AnalyzeDirect

Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, La Mantia L, Repice A, Solari A, Tedeschi G, Milanese C. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One. November 2014;9(11):e113371.

Full Text – Open Access

Publication Date
November 2014

How Analyze was Used
“Brain lesions were evaluated through MRI scans performed over 30 days prior to treatment (baseline) and at two years (study completion). … New lesion numbers were evaluated through dedicated software packages (Analyze 10.0), comparing each scan obtained at study completion with the corresponding baseline scan [see Methods S1 in File S1 for details].”

Keywords
Adverse Events
Disabilities
Drug Therapy
Interferons
Lesions
Magnetic Resonance Imaging (MRI)
Multiple Sclerosis
Neuroimaging

Author Affiliation(s)
Dipartimento di Neuroscienze, Psicologia, Farmaco e Salute del Bambino Università di Firenze, Firenze, Italy. (LM)

Neurologia 2, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy. (LM, AR)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy. (IT, GF, AS, CM)

Dipartimento di Neuroscienze, Sezione di Farmacologia, Università Politecnica delle Marche, Ancona, Italy. (SA)

Associazione Italiana Sclerosi Multipla (AISM), Fondazione Italiana Sclerosi Multipla (FISM), Genova, Italy. (MAB)

Dipartimento Universitario di Neurologia, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy. (MDB)

Unità di Neurologia – Multiple Sclerosis Center, I.R.C.C.S. Santa Maria Nascente Fondazione Don Gnocchi, Milano, Italy. (LLM)

Clinica Neurologica, Università di Napoli, Napoli, Italy. (GT)

ID# 975

Tags: Adverse Events, Disabilities, Drug Therapy, Interferons, Lesions, Magnetic Resonance Imaging (MRI), Multiple Sclerosis, Neuroimaging